Alexion is a global biopharmaceutical company focused on serving patients and families affected by rare diseases and devastating conditions through the discovery, development and commercialization of life-changing medicines. As a leader in rare diseases for more than 25 years, Alexion has developed and commercializes two approved complement inhibitors to treat patients with paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS), as well as the first and only approved complement inhibitor to treat anti-acetylcholine receptor (AchR) antibody-positive generalized myasthenia gravis (gMG) and neuromyelitis optica spectrum disorder (NMOSD). Alexion also has two highly innovative enzyme replacement therapies for patients with life-threatening and ultra-rare metabolic disorders, hypophosphatasia (HPP) and lysosomal acid lipase deficiency (LAL-D) as well as the first and only approved Factor Xa inhibitor reversal agent. In addition, the company is developing several mid-to-late-stage therapies, including a copper-binding agent for Wilson disease, an anti-neonatal Fc receptor (FcRn) antibody for rare Immunoglobulin G (IgG)-mediated diseases and an oral Factor D inhibitor as well as several early-stage therapies, including one for light chain (AL) amyloidosis, a second oral Factor D inhibitor and a third complement inhibitor. Alexion focuses its research efforts on novel molecules and targets in the complement cascade and its development efforts on hematology, nephrology, neurology, metabolic disorders, cardiology, ophthalmology and acute care. Headquartered in Boston, Massachusetts, Alexion has offices around the globe and serves patients in more than 50 countries.
Company profile
Ticker
ALXN
Exchange
Website
CEO
Ludwig Hantson
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
ALEXION PHARMACEUTICALS INC
SEC CIK
Corporate docs
Subsidiaries
Alexion Delaware Holding LLC • Alexion Services Latin America, Inc. • Alexion US Holdings LLC • Alexion US1 LLC • Alexion Pharma LLC • Alexion Holding LLC • Savoy Therapeutics Corp. • Wilson Therapeutics USA, Inc. • Syntimmune, Inc. • Achillion Pharmaceuticals, Inc. ...
IRS number
133648318
ALXN stock data
Latest filings (excl ownership)
SC TO-T/A
Third party tender offer statement (amended)
16 Nov 22
SC TO-T
Third party tender offer statement
18 Oct 22
SC TO-C
Information about tender offer
3 Oct 22
15-12G
Securities registration termination
2 Aug 21
EFFECT
Notice of effectiveness
26 Jul 21
EFFECT
Notice of effectiveness
26 Jul 21
EFFECT
Notice of effectiveness
26 Jul 21
EFFECT
Notice of effectiveness
26 Jul 21
EFFECT
Notice of effectiveness
26 Jul 21
EFFECT
Notice of effectiveness
26 Jul 21
Transcripts
ALXN
Earnings call transcript
2020 Q3
29 Oct 20
ALXN
Earnings call transcript
2020 Q2
30 Jul 20
ALXN
Earnings call transcript
2020 Q1
6 May 20
ALXN
Earnings call transcript
2019 Q4
30 Jan 20
ALXN
Earnings call transcript
2019 Q3
23 Oct 19
ALXN
Earnings call transcript
2019 Q2
24 Jul 19
ALXN
Earnings call transcript
2019 Q1
25 Apr 19
ALXN
Earnings call transcript
2018 Q4
4 Feb 19
ALXN
Earnings call transcript
2018 Q3
24 Oct 18
ALXN
Earnings call transcript
2018 Q2
26 Jul 18
Latest ownership filings
Financial summary
Quarter (USD) | Mar 21 | Dec 20 | Sep 20 | Jun 20 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 20 | Dec 19 | Dec 18 | Dec 17 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Institutional ownership, Q1 2023
0.0% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 1 |
Opened positions | 1 |
Closed positions | 0 |
Increased positions | 0 |
Reduced positions | 0 |
13F shares | Current |
---|---|
Total value | 13.00 k |
Total shares | 61.00 |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
Retirement | 61.00 | $13.00 k |